Gastrointestinal Cancer

James J. Harding, MD, discusses the goal of the phase III IMbrave150 trial in hepatocellular carcinoma (HCC).

Benjamin Weinberg, MD, discusses the role of cetuximab in treating metastatic colorectal cancer.

David H. Ilson, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in advanced gastric cancer.

The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application for avapritinib as a treatment for adult patients with fourth-line gastrointestinal stromal tumor.

Mike Cusnir, MD, discusses the utilization of ramucirumab in gastric cancer.

Girish Putcha, MD, PhD, discusses the use of blood-based screening assays in colorectal cancer (CRC).

Amir Khan, MD, discusses trends in the overall incidence of gastric cancer and colorectal cancer.

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Akshjot Puri, MD, discusses challenges facing older patients with pancreatic cancer.

Amir Khan, MD, discusses the rising incidence of gastric and colorectal cancers in young adult patients.

Modest activity has been observed with anti–PD-1 therapies for patients with gastric, esophageal, and hepatocellular carcinoma in later lines of therapy, but for patients with microsatellite instability–high tumors and other subgroups, treatment with these agents has shown benefit over chemotherapy in the first-line setting, according to recent data.